罗红霉素治疗耐多药肺结核病的疗效分析

目的 观察和评价罗红霉素缓释胶囊联合其它抗结核药物治疗耐多药肺结核病( MDR-PTB)的疗效.方法 选择我院住院的MDR-PTB患者120例做为研究对象,将其随机分为治疗组60例和对照组60例；对照组采用司帕沙星、丁氨卡那霉素及其他三种抗结核药物作为抗痨方案,治疗组在对照组基础上添加罗红霉素缓释胶囊,疗程12个月；观察两组转阴率和疗效.结果 第3个月末,治疗组痰菌转阴率为64％,对照组为42％,两组对比差异有统计学意义(x2=5.52,P＜0.05).疗程结束时,治疗组痰菌转阴率为91％,对照组为72％,两组比较差异有统计学意义(x2=6.62,P＜0.01)；治疗组病灶吸收显效率为89％,对照组为70％,两组对比差异有统计学意义(x2=6.14,P＜0.05).结论 罗红霉素缓释胶囊联合其它抗结核药物治疗MDR-PTB疗效肯定,对促进痰菌阴转、病灶吸收、空洞闭合有显著作用.

Roxithromycin for multidrug-resistant pulmonary tuberculosis

Objective To observe and assess the efficacy of roxithromycin sustained-release capsules com- bined with other anti-tuberculosis drugs in the treatment of multidrug-resistant pulmonary tuberculosis （ MDR-PTB ）. Methods 120 patients with MDR-PTB were selected as the subjecs of this study and then were randomly divided into study group and control group, 60 for each group. The control group received sparfloxacin, amikacin, and other three kinds of anti-tuberculosis drugs as anti-tuberculosis scheme, and the study group received roxithromycin for 12 months in addition to the therapies used in the control group. Results At the end of the third month, the sputum negative conversion rate was 64% in the study group and 42% in the control group, with a statistical significance （x2=5.52, P〈 0.05 ）. At the end of treatment, the sputum negative conversion rate was 91% in the study group and 72% in the control group, with a significant difference （ X2=6.62, P〈 0.01 ）. The rate of lesion absorption was 89% in the study group and 70% in the control group, with a statistical significance （ x2=6.14, P 〈 0.05 ）. Conclusions Roxithromycin sustained-release capsules combined with other anti-tuberculosis drugs is efficacious in the treatment of MDR-PTB and plays a role in promoting sputum negative conversion, lesion absorption, and cavity closure.